Equipment inflects, margins beat - but guidance optics cloud the print
23/07/26 -"Sartorius Stedim Biotech reported mixed Q2 26 numbers, with revenue below consensus (-2.8%) but underlying EBITDA ahead (+1.1%). The miss is largely an accounting effect from customer compensation ..."
Pages
69
Language
English
Published on
23/07/26
You may also be interested by these reports :
23/07/26
Sartorius Stedim Biotech reported mixed Q2 26 numbers, with revenue below consensus (-2.8%) but underlying EBITDA ahead (+1.1%). The miss is largely ...
17/07/26
We have revised our earnings estimates downwards and applied a 20% discount to peer-based valuation metrics to account for business challenges. ...
17/07/26
Getinge delivered a solid Q2 26, beating consensus on both sales and adjusted EBITA. ACT returned to positive sales growth after a weak Q1; order ...
16/07/26
China plans to implement VBP for capital equipment, which may pressure MedTech firms’ margins in the region. Additionally, the renewed US-Iran ...